Coherent Biopharma
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage biotech company developing bi-targeting XDC drugs to treat cancer and address undruggable targets.
Oncology
Technology Platform
Proprietary bi-targeting XDC (X-Drug Conjugate) technology designed to actively and specifically deliver diverse bioactive molecules (e.g., toxins, PROTACs, radiopharmaceuticals) to cells/tissues, overcoming undruggability.
Opportunities
Expanding its Bi-XDC platform to new payloads like PROTACs and radiopharmaceuticals, and leveraging AI collaborations to design next-generation conjugates for a broader range of undruggable targets beyond oncology.
Risk Factors
Clinical-stage risks associated with pivotal trial outcomes for lead assets, high competition in the ADC/XDC space from larger biopharma companies, and execution risks in global operations and commercialization.
Competitive Landscape
Competes in the targeted therapy and conjugate drug space (e.g., ADCs from Seagen/Astellas, Daiichi Sankyo). Differentiation lies in its dual-targeting approach (Bi-XDC) for enhanced specificity and its platform's versatility in delivering diverse payloads to overcome undruggability.